AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17072954 — intervention group
Group type: COMPARATOR
Intervention: Placebo for levodopa + 10% sucrose syrup for 7 days (Group 4)
Number of subjects: 139
Study 17072954 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both sugar and levodopa for 7 days (Group 5)
Number of subjects: 139
Study 17072954 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both sugar and levodopa for 14 days (Group 6)
Number of subjects: 139
Study 12924758 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with stable visual reference (walls and ceiling visible)
Number of subjects: 0
Study 12924758 — intervention group
Group type: COMPARATOR
Intervention: Condition without stable visual reference (curtains preventing view)
Number of subjects: 0
Study 11097085 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory remediation techniques
Number of subjects: 0
Study 11097085 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 9029458 — intervention group
Group type: EXPERIMENTAL
Intervention: Procera system for fabrication of crowns and fixed partial dentures
Number of subjects: 114
Study 8501336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with full strength bicarbonate buffer (4 g)
Number of subjects: 260
Study 8501336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with half strength bicarbonate buffer (2 g)
Number of subjects: 260
Study 8501336 — intervention group
Group type: COMPARATOR
Intervention: Full strength buffer without vaccine
Number of subjects: 260
Study 8501336 — intervention group
Group type: COMPARATOR
Intervention: Half strength buffer without vaccine
Number of subjects: 260
Study 3471750 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 500 mg
Number of subjects: 10
Study 3471750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 10
Study 3471750 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef 1 g
Number of subjects: 10
Study 3471750 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Number of subjects: 10
Study 2521060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 64
Study 29280043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 2 weeks
Number of subjects: 173
Study 29280043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 18 weeks plus weekly paclitaxel
Number of subjects: 173
Study 29280043 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 173
Study 29280043 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT
Number of subjects: 173
Study 29145824 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 120
Study 29145824 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 120
Study 29145824 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 120
Study 29145824 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (elderly subgroup)
Number of subjects: 120
Study 29145824 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV
Number of subjects: 120
Study 29145824 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP
Number of subjects: 120
Study 26321318 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg orally, twice daily)
Number of subjects: 55
Study 26321318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23542954 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Intervention (SI)
Number of subjects: 126
Study 23542954 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 126
Study 21346166 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive animation video
Number of subjects: 211
Study 21346166 — intervention group
Group type: COMPARATOR
Intervention: No video
Number of subjects: 211
Study 21346166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 18277878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group training protocol (exercise therapy, back school, behavioral principles)
Number of subjects: 114
Study 18277878 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy (guideline group)
Number of subjects: 114
Study 16547634 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (8 mg/day)
Number of subjects: 40
Study 16547634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/day)
Number of subjects: 40
Study 16547634 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (8 mg/day)
Number of subjects: 40
Study 16547634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 40
Study 16547634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14762840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) used in 21 patients (Group A)
Number of subjects: 42
Study 14762840 — intervention group
Group type: COMPARATOR
Intervention: Continuous clamping alone used in 21 patients (Group B)
Number of subjects: 42
Study 11712620 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day)
Number of subjects: 78
Study 11712620 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 78
Study 9225527 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 32
Study 9225527 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 32
Study 9225527 — intervention group
Group type: COMPARATOR
Intervention: Comparison between halothane and isoflurane
Number of subjects: 32
Study 8356591 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP (160 mg)‐SMX (800 mg) twice daily three days per week (group B)
Number of subjects: 58
Study 8356591 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP (160 mg)‐SMX (800 mg) twice daily seven days per week (group C)
Number of subjects: 58
Study 8356591 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 58
Study 3306440 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine (120 mg/day)
Number of subjects: 0
Study 3306440 — intervention group
Group type: COMPARATOR
Intervention: Meprobamate (2,400 mg/day)
Number of subjects: 0
Study 3306440 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine (2.5-5.0 mg/kg, infusional application)
Number of subjects: 0
Study 30304749 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available formula diet supplemented with oats fibers
Number of subjects: 36
Study 30304749 — intervention group
Group type: COMPARATOR
Intervention: Control group received a comparably restricted diet (approx. 1000 kcal/d)
Number of subjects: 36
Study 27432604 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 125 mg twice daily
Number of subjects: 0
Study 27432604 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg twice daily
Number of subjects: 0
Study 27432604 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times daily
Number of subjects: 0
Study 23894101 — intervention group
Group type: EXPERIMENTAL
Intervention: ED+/MR-
Number of subjects: 238
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 162
Study 22893770 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 162
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 162
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue antiemetics
Number of subjects: 162
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative weight gain
Number of subjects: 162
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary score of postoperative symptoms
Number of subjects: 162
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress coping capacity
Number of subjects: 162
Study 22893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 162
Study 20541180 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 36
Study 20541180 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation plus self-instruction to postpone worrying
Number of subjects: 36
Study 18987098 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily, mean dose 24 mg)
Number of subjects: 7599
Study 18987098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 18987098 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 15816793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/day in week 1, 16 mg/day in week 2, 24 mg/day in week 3)
Number of subjects: 30
Study 15816793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15816793 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron and Placebo
Number of subjects: 30
Study 12873937 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia
Number of subjects: 40
Study 12873937 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane inhaled anesthesia
Number of subjects: 40
Study 11176472 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bethanechol
Number of subjects: 22
Study 11176472 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22
Study 9287928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes placed antero-superiorly
Number of subjects: 106
Study 9287928 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes placed antero-inferiorly
Number of subjects: 106
Study 8281565 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 165
Study 8281565 — intervention group
Group type: COMPARATOR
Intervention: Control (no-gum)
Number of subjects: 165
Study 3557757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine 2 g
Number of subjects: 40
Study 3557757 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g
Number of subjects: 40
Study 30979507 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP-ZEEP in volume-controlled mode
Number of subjects: 19
Study 30979507 — intervention group
Group type: COMPARATOR
Intervention: PEEP-ZEEP in pressure-controlled mode
Number of subjects: 19
Study 30979507 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC application
Number of subjects: 19
Study 29461411 — intervention group
Group type: EXPERIMENTAL
Intervention: Loco First (n = 50)
Number of subjects: 140
Study 29461411 — intervention group
Group type: EXPERIMENTAL
Intervention: Object First (n = 48)
Number of subjects: 140
Study 29461411 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) (n = 42)
Number of subjects: 140
Study 28623425 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week high-intensity strength and sprint training program (EX)
Number of subjects: 72
Study 28623425 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 72
Study 25889522 — intervention group
Group type: EXPERIMENTAL
Intervention: IV inoculation with 50 PfSPZ
Number of subjects: 18
Study 25889522 — intervention group
Group type: EXPERIMENTAL
Intervention: IV inoculation with 200 PfSPZ
Number of subjects: 18
Study 25889522 — intervention group
Group type: EXPERIMENTAL
Intervention: IV inoculation with 800 PfSPZ
Number of subjects: 18
Study 25889522 — intervention group
Group type: EXPERIMENTAL
Intervention: IV inoculation with 3,200 PfSPZ
Number of subjects: 18
Study 25889522 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct venous inoculation with 3,200 PfSPZ
Number of subjects: 18
Study 23211012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX + 0.05% CPC (test-group)
Number of subjects: 30
Study 23211012 — intervention group
Group type: COMPARATOR
Intervention: Placebo-solution (placebo-group)
Number of subjects: 30
Study 23211012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both decontamination procedures
Number of subjects: 30
Study 20215961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 1000
Study 20215961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 1000
Study 20215961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg
Number of subjects: 1000
Study 20215961 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 1000
Study 20215961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 19734766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled intravitreal injection
Number of subjects: 60
Study 19734766 — intervention group
Group type: COMPARATOR
Intervention: Straight intravitreal injection
Number of subjects: 60
Study 19734766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17392720 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug cocktail (Inje cocktail)
Number of subjects: 12
Study 15042543 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran, 1,000 mg IV
Number of subjects: 25
Study 15042543 — intervention group
Group type: COMPARATOR
Intervention: Normal saline IV (placebo)
Number of subjects: 25
Study 11556875 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Number of subjects: 0
Study 11556875 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor therapy
Number of subjects: 0
Study 11556875 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori testing
Number of subjects: 0
Study 11556875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine Zeng Sheng Ping for severe dysplasia
Number of subjects: 9336
Study 11717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets of riboflavin Calcium for mild dysplasia
Number of subjects: 9336
Study 11717931 — intervention group
Group type: COMPARATOR
Intervention: Placebo for control group
Number of subjects: 9336
Study 10150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine once daily (up to 20 mg/day)
Number of subjects: 33
Study 10150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine twice daily (up to 20 mg/day)
Number of subjects: 33
Study 10150222 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (before and after nisoldipine)
Number of subjects: 33
Study 10150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine once daily
Number of subjects: 33
Study 3138906 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat intake
Number of subjects: 16
Study 3138906 — intervention group
Group type: COMPARATOR
Intervention: Low fat intake
Number of subjects: 16
Study 30817599 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 43
Study 29187151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2.5 μg/kg (group D)
Number of subjects: 135
Study 29187151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 6 mg/kg (group K)
Number of subjects: 135
Study 29187151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg and oral ketamine 3 mg/kg (group DK)
Number of subjects: 135
Study 25924803 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (1 mg/kg/day i.v. methylprednisolone intraoperatively and at postoperative days 1-5)
Number of subjects: 310
Study 25924803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 23739650 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/simvastatin 20 mg
Number of subjects: 68
Study 23739650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 68
Study 21763461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouth rinse
Number of subjects: 45
Study 21763461 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine mouth rinse
Number of subjects: 45
Study 21763461 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Tulsi extract mouth rinse
Number of subjects: 45
Study 21763461 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all three mouth rinses
Number of subjects: 45
Study 19353707 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 46
Study 19353707 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 46
Study 16759902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 14
Study 16759902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15320919 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding to establish a school-based breakfast club
Number of subjects: 0
Study 15320919 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast club attendees
Number of subjects: 0
Study 15320919 — intervention group
Group type: COMPARATOR
Intervention: Control (no funding)
Number of subjects: 0
Study 11473139 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot methods (same-day telephone interviews or one-off weekly diaries)
Number of subjects: 375
Study 11473139 — intervention group
Group type: COMPARATOR
Intervention: 6 month diaries
Number of subjects: 375
Study 11473139 — intervention group
Group type: COMPARATOR
Intervention: Participants attending hospital outpatient clinics
Number of subjects: 375
Study 9409501 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 50
Study 9409501 — intervention group
Group type: COMPARATOR
Intervention: No oxygen therapy (Control)
Number of subjects: 50
Study 7773823 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mg in 20 ml NaCl)
Number of subjects: 40
Study 7773823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 ml, 0.375%)
Number of subjects: 40
Study 7773823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and morphine
Number of subjects: 40
Study 7773823 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 ml, control group)
Number of subjects: 40
Study 2119878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen
Number of subjects: 395
Study 2119878 — intervention group
Group type: COMPARATOR
Intervention: Non-cisplatin-containing regimen
Number of subjects: 395
Study 2119878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 395
Study 2119878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine
Number of subjects: 395
Study 344003 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone emollient cream (0.25 percent)
Number of subjects: 1000
Study 344003 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate cream (0.1 percent)
Number of subjects: 1000
Study 31733126 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 374
Study 28936902 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 1942
Study 28793995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) 800-1000 kcal/d for 8 weeks
Number of subjects: 191
Study 28793995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical changes during the LCD
Number of subjects: 191
Study 28793995 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline expression added to clinical changes model
Number of subjects: 191
Study 28793995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical models for glycemic improvements
Number of subjects: 191
Study 28793995 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression changes during the LCD added to clinical models
Number of subjects: 191
Study 25460258 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation about the mood-as-input hypothesis
Number of subjects: 0
Study 25460258 — intervention group
Group type: COMPARATOR
Intervention: Befriending control group
Number of subjects: 0
Study 24502231 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based physiotherapy
Number of subjects: 30
Study 24502231 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy
Number of subjects: 30
Study 22967016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during high-dose chemotherapy
Number of subjects: 78
Study 22967016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral cryotherapy)
Number of subjects: 78
Study 22967016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 78
Study 20418097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 246
Study 20418097 — intervention group
Group type: COMPARATOR
Intervention: No cetuximab
Number of subjects: 246
Study 16860921 — intervention group
Group type: EXPERIMENTAL
Intervention: High depressive symptoms group (CES-D*16)
Number of subjects: 55
Study 16860921 — intervention group
Group type: COMPARATOR
Intervention: Low depressive symptoms group (CES-D < 16)
Number of subjects: 55
Study 15616083 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIA remifentanil (0.27‐0.93 microg/kg per bolus)
Number of subjects: 88
Study 15616083 — intervention group
Group type: COMPARATOR
Intervention: IV infusion of meperidine (150 mg, range 75-200 mg)
Number of subjects: 88
Study 11864867 — intervention group
Group type: EXPERIMENTAL
Intervention: Durnin-Womersley formula
Number of subjects: 54
Study 11864867 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 54
Study 10443885 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1a 22 microg (6 mIU)
Number of subjects: 560
Study 10443885 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1a 44 microg (12 mIU)
Number of subjects: 560
Study 10443885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 10443885 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1a 22 microg (6 mIU) and 44 microg (12 mIU)
Number of subjects: 560
Study 10443885 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial monthly scanning cohort
Number of subjects: 560